Dr. Chiarle received the 2022 ALK-Positive Research Awards from ALK Positive and LUNGevity Foundation (12/01/2022)

ALK Positive and LUNGevity Foundation Announce Recipients of the 2022 ALK-Positive Research Awards, they are Trever Bivona, Roberto Chiarle, Angel Qin. To transform advanced ALK-positive lung cancer into a chronic or curable disease, ALK Positive to award $1.75 million through their research award program. Click here to see more.

The Boston Investment Conference selected Dr. Chiarle as its 2022 awardee (12/01/22)
The Boston Investment Conference selected Dr. Chiarle as its 2022 awardee. Funds from the November 1 conference will enable him to launch the crucial human trials needed to combat neuroblastoma and save lives. His critical work will pave the way to new treatments and offer fresh hope for children with cancer and their families. Click here to see more.
Dr. Chiarle was selected from the DF/HCC Lung Cancer Program to lead the SPORE projects 1 (11/30/22)

The goal of DF/HCC Lung Cancer Specialized Program of Research Excellence (SPORE)  Project 1 is to develop a therapeutic peptide vaccine against ALK in the treatment of patients with tyrosine kinase inhibitor-resistant ALK-positive lung cancer. Click here to see more.

The video with Roberto Chiarle and Elisa Bergaggio starring for the ALK.CAR T cell trial (11/28/22)

Meet the Boston Children's pathologist leading a promising treatment for a devastating childhood cancer. See the video shared at the 2022 Boston Investment Conference.

Dr. Chiarle won the LLS SCOR grant on ALCL lymphoma (10/10/22)

Peripheral T-cell lymphomas (PTCLs) are poorly understood and patients with PTCL are underserved by current therapies. This project aims to establish preclinical evidence for combination strategies that integrate CCR7/PI3 kinase inhibition to eradicate minimal residual disease in PTCLs.  Click here to see more.

Our work on retrotransposon LINE1 insertion in CRISPR-based gene editing systems was published by Nature Communications (07/18/22)

Our work systematically assessing the safty issue of CRISPR-based gene editing systems from aspect of retrotransposon LINE1 insertion was published online by Nature Communications. The article can be found here. Also see the corresponding reports from BCH and AZO Life Sciences.

Dr. Taek-Chin Cheong received the OFD fellowship awards (07/16/22)

Lab member, Dr. Taek-Chin Cheong, received a fellowship awards sponsored by the Office of Faculty Development (OFD) and the Research Committees (BTREC and CTREC). Congratulations! Click here to see more.

Our work on molecular mechanism of resistance to ALK inhibitors in ALK+ ALCL was published by Blood (02/04/22)

Our work that tyrosine phosphatases regulate resistance to ALK inhibitors in ALK+ anaplastic large cell lymphoma was published online by Blood. The article can be found here.

Lab member, Rafael, got his lovely daughter, and becomes a father now. (06.30.2020)

Lab member, Rafael, just got his very lovely girl, in June 2020. This a wonderful time for Rafael's life and family. Bless he becomes a farther now!

Lab member, Elif, got her PhD degree. (01.31.2019)

Lab member, Elif Karaca, just passed her defense and got her PhD in January, 2019. Congratulations!

Our work on WASP as a tumor suppressor was published by Nature Medicine!(12.03.2018)

Our work that Wiskott–Aldrich syndrome protein (WASP) is a tumor suppressor in T cell lymphoma was published online by Nature Medicine today. The article can be found here

Lab member, Tao Chen, had his cute doughter. (11.20.2018)

Lab member, Tao, had his lovely daughter in November 2018. That was a really wonderful gift for Tao's life and his family. Bless them at this moment!

Lab member, Rafael Blasco-Patiño, got married. (06.28.2017)

Lab member, Rafael , just got married in June,2017. Congratulations on the start of something beautifulCongratulations on their union as life partners!

Lab member, Dr. Pighi, gave a presentation on FBXO11 mutation in Lymphoma on AACR (05.08.2017)

The work on FBXO11 in lymphoma selected as an oral presentation at the plenary session of the meeting Hematologic Malignancies: Translating Discoveries to Novel Therapies organazied by the AACR, May 6-9, 2017; Boston, MA.

Our work on PI3K δ blockade was published by Nature (02/15/2017)

Our work that PI3K δ blockade increases genomic instability in B cells was published by Nature today. The article can be found here. A Nature News and Views, Cancer: A targeted treatment with off-target risks, written by Prof. Fruman and O'Brien from University of California can be found here.

Dr. Chiarle won a grant for a phase I clinical trial using an ALK vaccine for ALK-rearranged lung cancers (03.01.2016)

Dr. Chiarle has been awarded a Bridge Project Extension grant to test the efficacy of a therapeutic ALK vaccine in ALK-rearranged non-small cell lung cancer patients in collaboration with Dr. Darrell Irvine (MIT-Koch Institute) and Dr. Mark Awad (DFCI). The vaccine is currently seeking IND approval from FDA (03/01/2016)

Congratulations to Dr. Chiarle for receiving a NIH R01 grant (10.01.2015)

Our lab PI, Roberto Chiarle, received a NIH R01 grant from NHLBI to investigate molecular resistance mechanism of ALK inhibitor and develop innovative therapies of ALK-rearranged cancer. Congratulations!

Dr. Chiarle has been elected as Member of the AACR and of the ASH. (02.13.2014)

Lab PI, Roberto Chiarle, has been elected as Member of the American Association for Cancer Research (AACR) and of the American Association of Hematology (ASH) in Feb, 2014. Congratulations!

Lab member, Mara, just got her PhD. (01.31.2014)

Lab member, Mara, just passed her defense and got her PhD in Jan, 2014. Congratulations!

Lab member, Taek-Chin, got his lovely baby. (01.27.2014)

Lab member, Taek-Chin, had his baby in January, 2014. The baby, a quite lovely girl, was born on Saturday in BIDMC. She is a definitely wonderful gift for Taek's life and his family. Bless Taek becomes a farther now!